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Seoul, Jeonju, Gwangju, Ilsan, Cheonan, Jinju, Bucheon, Daejeon, Incheon, Busan, and Seongnam,
Republic of KoreaObjectives This study sought to compare everolimus-eluting stents (EES) versus Resolute zotarolimus-
eluting stents (ZES) in terms of patient- or stent-related clinical outcomes in an “all-comer” group of
patients with diabetes mellitus (DM) who underwent percutaneous coronary intervention.
Background DM signiﬁcantly increases the risk of adverse events after percutaneous coronary
intervention. The efﬁcacy and safety of second-generation drug-eluting stents, in particular EES versus
ZES, in patients with DM have not been extensively evaluated.
Methods Patients with DM (1,855 of 5,054 patients, 36.7%) from 2 prospective registries (the
EXCELLENT [Efﬁcacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting] registry
and RESOLUTE-Korea [Registry to Evaluate the Efﬁcacy of Zotarolimus-Eluting Stent]) who were treated
with EES (n ¼ 1,149) or ZES (n ¼ 706) were compared. Stent-related outcome was target lesion failure
(TLF), and patient-oriented composite events were a composite of all-cause mortality, any myocardial
infarction, and any revascularization.
Results Despite a higher risk patient proﬁle in the ZES group, both TLF (43 of 1,149 [3.7%] vs. 25 of
706 [3.5%], p ¼ 0.899) and patient-oriented composite events (104 of 1,149 [9.1%] vs. 72 of 706
[10.2%], p ¼ 0.416) were similar between the EES and ZES in patients with DM at 1 year. In those
without DM, EES and ZES also showed comparable incidence of TLF (39 of 1,882 [2.1%] vs. 33 of 1,292
[2.6%], p ¼ 0.370) and patient-oriented composite events (119 of 1,882 [6.3%] vs. 81 of 1,292 [6.3%],
p ¼ 0.951), which were all signiﬁcantly lower than in the DM patients. These results were corroborated
by similar ﬁndings from the propensity score-matched cohort. Upon multivariate analysis, chronic
renal failure was the most powerful predictor of TLF in DM patients (hazard ratio: 4.39, 95% conﬁdence
interval: 1.91 to 10.09, p < 0.001).
Conclusions After unrestricted use of second-generation drug-eluting stents in all-comers
receiving percutaneous coronary intervention, both EES and ZES showed comparable clinical
outcomes in the patients with DM up to 1 year of follow-up. DM compared with non-DM
patients showed signiﬁcantly worse patient- and stent-related outcomes. Nonetheless, overall
incidences of TLF were low, even in the patients with DM, suggesting excellent safety and
efﬁcacy of both types of second-generation drug-eluting stents in this high-risk subgroup of
patients. (J Am Coll Cardiol Intv 2014;7:471–81) ª 2014 by the American College of Cardiology
Foundation
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472Implantation of drug-eluting stents (DES) has demon-
strated superiority in reducing the need for repeat revascu-
larization compared with bare-metal stents in substudies
of randomized controlled trials (RCT), a multicenter
observational registry, and meta-analysis in patients with
diabetes mellitus (DM) (1–4). Nonetheless, DM is still
among the most important risk factors for adverse clinical
events, even in the DES era (5,6). Second-generation DESSee page 494have almost completely replaced ﬁrst-generation DES, in
the treatment of coronary artery disease. The representative
second-generation DES, everolimus-eluting stents (EES)
have shown noninferior or comparable clinical outcomes
with ﬁrst-generation DES in patients with DM (7,8).From the *Department of Internal M
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Abbreviations
and Acronyms
CI = conﬁdence interval
DES = drug-eluting stent(s)
DM = diabetes mellitus
EES = everolimus-eluting
stent(s)
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RCT = randomized controlled
trial(s)
RR = relative risk
ST = stent thrombosis
TLF = target lesion failure
TLR = target lesion
revascularization
ZES = zotarolimus-eluting
stent(s)Another second-generation DES,
the Resolute zotarolimus-eluting
stent (ZES), recently received U.S.
Food and Drug Administration
labeling for use in patients with
DM (9). However, head-to-head
comparisons between EES and
ZES have been limited to 2 re-
presentative randomized con-
trolled trials (RESOLUTE All
Comers [Randomized Compar-
ison of a Zotarolimus-Eluting
StentWith anEverolimus-Eluting
Stent] trial and TWENTE [A
Prospective Randomized Trial
of Zotarolimus-Eluting Stents
and Everolimus-Eluting Stents in
Patients With Coronary Artery
Disease]) (10,11). Recently, we
published the 1-year comparison
of EES versus ZES in 5,054 pa-
tients from 2 multicenter registries(EXCELLENT [Efﬁcacy of Xience/Promus Versus Cypher
in Reducing Late Loss After Stenting] registry andedicine and Cardiovascular Center, Seoul Na-
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Internal Medicine and Cardiovascular Center,RESOLUTE-Korea [Registry to Evaluate the Efﬁcacy of
Zotarolimus-Eluting Stent]) (12). To the best of our
knowledge, there are limited data regarding direct compari-
son of EES with ZES in patients with DM. Therefore, we
compared EES versus ZES in terms of patient- and stent-
related clinical outcomes in all-comers with DM undergoing
percutaneous coronary intervention (PCI) with second-
generation DES.
Methods
An extended description of study methods are presented in
the Online Appendix.
Study design and patient population. This study evaluated
1-year clinical outcomes of EES (Xience V, Abbott
Vascular, Abbott Park, Illinois) and zotarolimus-eluting
stents (ZES) (Resolute, Medtronic Cardiovascular, Min-
neapolis, Minnesota) in the patients with DM from the
EXCELLENT and RESOLUTE-Korea registries, which
enrolled all-comers treated with 1 EES or ZES (3,056
patients in 29 participating centers and 1,998 patients in
25 participating centers, respectively) without exclusions
(12). Among the 5,054 patients, 36.7% (n ¼ 1,855) had type
2 DM and were treated with EES (1,149 of 3,056 patients,
37.9%) or ZES (706 of 1,998 patients, 35.3%). The ﬂow of
patients in the study is presented in Figure 1.
Follow-up. After index PCI, follow-ups were performed
at 1, 3, 9, and 12 months; angiography was optional at
9 months. All relevant medical records were reviewed for
any clinical event and adjudicated by an external clinical
event committee. Using the Korean health system’s unique
identiﬁcation numbers, the vital status of all patients was
cross-checked. The study protocol was approved by the
ethics committee at each participating center and was con-
ducted according to the principals of the Declaration of
Helsinki. All patients provided written informed consent.
Deﬁnitions and outcome analysis. DM (type 1 or type 2)
was deﬁned as either a previous diagnosis of DM treated
with pharmacologic or nonpharmacologic measure, or a new
DM was deﬁned according to the American DiabetesBusan National University Hospital, Busan, Republic of Korea; and the kkDepartment
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Korea. The 2 registries were also funded from unrestricted grants from Abbott
Vascular Republic of Korea and Medtronic Republic of Korea. The funding sources
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Figure 1. Flow of Participants Diagram
CVA ¼ cerebrovascular accident; EES ¼ everolimus-eluting stent(s); EXCELLENT ¼ Efﬁcacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting]
registry; MI ¼ myocardial infarction; RESOLUTE-Korea ¼ Registry to Evaluate the Efﬁcacy of Zotarolimus-Eluting Stent; TLR ¼ target lesion failure; ZES-R ¼ Resolute
zotarolimus-eluting stent(s).
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473Association as history of either presence of classic symptoms
of DM with unequivocal elevation of plasma glucose (2 h
post-prandial or random of >200 mg/dl) or fasting plasma
glucose elevation on >2 occasions of 126 mg/dl during
hospitalization. Patients were considered insulin-treated if
they were taking insulin. Patients were considered non-
insulin-treated if they were taking only oral hypoglycemic
agents or were on a therapeutic lifestyle modiﬁcation only or
both oral agents and therapeutic life-style modiﬁcation. The
primary stent-related clinical outcome was target lesion
failure (TLF), deﬁned as cardiac death, target vessel
myocardial infarction (MI), or clinically indicated target
lesion revascularization (TLR) by percutaneous or surgical
methods at 12 months. All clinical outcomes were deﬁned
according to the Academic Research Consortium (13,14).
The key secondary outcomes were patient-oriented com-
posite events, which included all-cause mortality, any MI,
and any revascularization. Other secondary outcomes
included individual components of the primary and key
secondary clinical outcomes; target or non–target vessel MI;
clinically driven or angiographically driven repeat revascu-
larization including TLR or target vessel revascularization
(13); and stent thrombosis (ST) deﬁned according to the
Academic Research Consortium as deﬁnite, probable, or
possible (13,14). The indication of PCI was considered “off-
label” if any of the following features were present: serumcreatinine concentration 140 mmol/l (1.6 mg/dl); left
ventricular ejection fraction <30%; an acute MI within the
previous 72 h; >1 lesion per vessel; 2 vessels treated with
a stent; a lesion length 28 mm; or a bifurcated lesion,
bypass graft, in-stent restenosis, unprotected left main cor-
onary artery, presence of thrombus, or total occlusion
(15,16). Chronic renal failure was deﬁned as an estimated
glomerular ﬁltration rate <60 ml/min calculated by means
of the Cockcroft-Gault formula.
Statistical analysis. The analysis was performed in 2 parts.
First, analysis and comparison of primary and secondary
clinical outcomes were conducted in the crude population.
Second, a propensity score matched population was selected
to adjust for uneven distribution of baseline characteristics.
Comparison of treatment effect between 2 stent groups
was stratiﬁed by DM versus non-DM. Categorical variables
were presented as numbers and relative frequencies (per-
centages) and were compared using the chi-square test or
the Fisher exact test for independent groups and a 2-tail
p value. Normally distributed continuous variables were
expressed as means  SD and were analyzed using the in-
dependent sample t test. Kaplan-Meier analysis was used to
calculate cumulative incidence of primary and secondary
clinical outcomes, and log-rank test or Breslow test was used
to compare between-group differences, as appropriate.
Because differences in baseline clinical and angiographic
Table 1. Baseline Clinical Characteristics of Patients in Diabetes Population*
Total
(N ¼ 1,855)
EES
(n ¼ 1,149)
ZES-R
(n ¼ 706) p Value
Demographics
Age, yrs 64.6  9.8 64.5  9.7 64.9  10.0 0.416
Male 1,187 (64.0) 739 (64.3) 448 (63.5) 0.727
BMI, kg/m2 25.1  10.5 25.3  13.2 25.0  3.1 0.579
Diabetes mellitus treatment
No treatment 209 (11.3) 140 (12.2) 69 (9.8) 0.113
Life-style modiﬁcation 82 (4.4) 50 (4.4) 32 (4.5) 0.907
OHA 1,350 (72.8) 850 (74.0) 500 (70.8) 0.147
Insulin 255 (13.7) 140 (12.2) 115 (16.3) 0.015
Metabolic status
HbA1C, % 7.5  1.5 7.4  1.5 7.6  1.4 0.031
HbA1C <7% 588 (42.3) 396 (44.6) 192 (38.2) 0.021
Creatinine, mg/dl 1.4  1.7 1.3  1.6 1.4  1.7 0.350
eGFR, ml/min/1.73 m2 65.7  28.8 65.7  28.0 65.6  30.0 0.970
Lipids proﬁle, mg/dl
Total cholesterol 165.0  43.8 166.3  44.3 163.0  43.1 0.125
LDL cholesterol 97.8  34.6 98.9  34.9 95.6  33.8 0.066
LDL <100 mg/dl 910 (56.2) 571 (54.6) 339 (59.1) 0.094
HDL cholesterol 41.2  11.3 41.5  11.6 40.8  10.8 0.212
Triglycerides 152.4  113.2 151.3  100.3 154.3  132.0 0.595
Coexisting condition
Hypertension 1,383 (74.8) 851 (74.5) 532 (75.4) 0.700
Dyslipidemia 1,287 (71.8) 758 (69.7) 529 (74.9) 0.018
Peripheral artery disease 39 (2.1) 24 (2.1) 15 (2.1) 0.997
Chronic renal failure 129 (7.0) 70 (6.2) 59 (8.4) 0.075
Cardiac risk factors
Current smoker 475 (26.1) 299 (26.5) 176 (25.3) 0.583
Previous PCI 338 (18.3) 204 (17.8) 134 (19.0) 0.536
Previous CABG 44 (2.4) 22 (1.9) 22 (3.1) 0.116
Previous MI 134 (7.2) 89 (7.8) 45 (6.4) 0.269
Previous CHF 47 (2.6) 27 (2.4) 20 (2.8) 0.650
Previous CVA 184 (10.0) 120 (10.6) 64 (9.1) 0.299
Family history of CAD 92 (5.1) 61 (5.6) 31 (4.4) 0.275
LVEF 58.3  11.9 58.7  11.8 57.6  12.0 0.077
LV dysfunction, LVEF <30% 36 (2.2) 19 (1.9) 17 (2.7) 0.297
Continued on the next page
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474characteristics could affect the primary and secondary clinical
outcomes, a 1:1 matched analysis without replacement was
performed using propensity scores. The propensity scores
were estimated with multiple logistic regression analysis that
included all covariates listed in Tables 1 and 2, except
outcome variables. Logistic regression model was separately
conducted to generate a propensity score, which was the
probability that a patient received a ZES or which was the
probability that a patient had DM. The discrimination
and calibration abilities of the propensity score model were
assessed by C-statistics (0.652 for the ﬁrst model according
to the stent types and 0.705 for the second model according
to the presence or not of DM) and the Hosmer-Lemeshow
statistics (chi-square: 8.375, p ¼ 0.398 and chi-square:7.107, p ¼ 0.525, respectively). The matching processes
were also performed separately to compare the clinical out-
comes between EES and ZES, or between patients with or
without DM. For matching, nearest neighbor matching
with a caliper width of 0.6 SD was used because this value
has been shown to eliminate over 90% of the bias in the
observed confounders (17). Success of the propensity score
matching was assessed by calculating the percentage of
standardized differences of the baseline characteristics. A
<10% difference supports the assumption of a balance
between matched groups (18). A Cox proportional hazard
regression model was used to identify independent pre-
dictors of primary clinical outcome TLF. The covariates
used in multivariate analysis were selected if they were
Table 1. Continued
Total
(N ¼ 1,855)
EES
(n ¼ 1,149)
ZES-R
(n ¼ 706) p Value
Clinical indication of PCI 0.020
Stable angina 663 (35.8) 437 (38.2) 226 (32.0) 0.007
Unstable angina 670 (36.2) 413 (36.1) 257 (36.4) 0.921
Acute MI 446 (24.1) 249 (21.8) 197 (27.9) 0.003
NSTEMI 228 (12.3) 128 (11.2) 100 (14.2) 0.069
STEMI 218 (11.8) 121 (10.6) 97 (13.7) 0.045
Silent ischemia 71 (3.8) 45 (3.9) 26 (3.7) 0.805
Complexity of CAD
Angiographic disease extent 0.263
1VD 687 (37.2) 442 (38.6) 245 (34.9)
2VD 595 (32.2) 360 (31.5) 235 (33.4)
3VD 565 (30.6) 342 (29.9) 223 (31.7)
Treated lesions/patients, n 1.54  0.80 1.53  0.77 1.56  0.85 0.436
1 ISR 150 (8.1) 100 (8.7) 50 (7.1) 0.221
1 bifurcation 319 (17.2) 158 (13.8) 161 (22.8) <0.001
1 thrombotic total 175 (9.4) 98 (8.5) 77 (10.9) 0.102
1 small vessel* 471 (25.4) 299 (26.0) 172 (24.4) 0.442
1 long lesiony 872 (47.0) 501 (43.6) 371 (52.5) <0.001
Multivessel PCI 626 (33.7) 392 (34.1) 234 (33.1) 0.686
GP IIb/IIIa antagonist use 51 (2.9) 27 (2.6) 24 (3.4) 0.385
1off-label usez 1432 (77.7) 851 (74.1) 581 (82.3) <0.001
Values are mean SD or n (%). *Small vessel denotes lesion with reference diameter 2.75 mm. yLong lesion denotes lesion with length 28 mm.
zOff-label use: Patients with off-label indication were deﬁned as having 1 of the following characteristics: serum creatinine concentration of 140
mmol/l (1.6 mg/dl) or more; LVEF <30%; an acute MI within the previous 72 h; 1 lesion per vessel; 2 vessels treated with a stent; a lesion 28
mm; or bifurcated lesion, bypass graft, in-stent restenosis, unprotected left main coronary artery, presence of thrombus, or total occlusion.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CVA ¼ cere-
brovascular accident; EES ¼ everolimus-eluting stents; eGFR ¼ estimated glomerular ﬁltration rate; GP ¼ glycoprotein; HBA1C ¼ glycosylated
hemoglobin; HDL ¼ high-density lipoprotein; ISR ¼ in-stent restenosis; LDL ¼ low-density lipoprotein; LVEF ¼ left ventricular ejection fraction;
MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; OHA ¼ oral hypoglycemic agents; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; VD ¼ vessel disease; ZES-R ¼ Resolute zotarolimus-eluting stents.
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475signiﬁcantly different between the 2 groups (p < 0.1) or if
they had predictive values. All probability values were
2-sided and p values < 0.05 were considered statistically
signiﬁcant. The statistical package SPSS (version 18.0,
SPSS Inc., Chicago, Illinois) and R programming language
(version 2.15.2, R Foundation for Statistical Computing,
Vienna, Austria) were used for statistical analyses.
Results
Baseline patient and angiographic characteristics of diabetes
population. Among the overall population of both registries
(n ¼ 5,054), the ﬁnal analysis population was 1,855 patients
with DM with 2,688 lesions (EES: 1,149 patients with
1,660 lesions, ZES: 706 patients with 1,028 lesions), and
3,174 nondiabetic patients with 4,365 lesions (EES: 1,882
patients with 2,557 lesions, ZES: 1,292 patients with 1,808
lesions), after exclusion of the patients with unknown status
of DM. In the overall population of 5,054 patients,
55 (1.1%) in the EES group and 32 (0.6%) patients in the
ZES group, respectively, were lost to follow-up before the
12-month follow-up visit; however, all were conﬁrmed alive.Baseline clinical and angiographic characteristics are pre-
sented in Tables 1 and 2, respectively. Among the 1,855
patients, 209 patients (11.3%) were newly diagnosed with
DM according to the criteria of the American Diabetes
Association at the time of index procedure. The proportion
of newly diagnosed DM was not different between the
2 stent groups (12.2% in the EES group vs. 9.8% in the
ZES group, p ¼ 0.113). Most of the patients with DM
(72.8%) were on oral hypoglycemic agents. Of the 1,855
patients with diabetes, 255 patients (13.7%) required insulin
treatment. Glycemic control, quantiﬁed by hemoglobin A1C,
was signiﬁcantly poorer in insulin-treated than in non-
insulin-treated patients (8.1  1.8% vs. 7.4  1.3% for
insulin- vs. non-insulin-treated diabetics, p < 0.001).
Regarding baseline risk factors, both stent groups were
largely comparable. However, the proportion of insulin-
treated patients was higher (12.2% vs. 16.3%, p ¼ 0.015)
and glycemic control was worse (hemoglobin A1C: 7.4 
1.5% vs. 7.6  1.4%, p ¼ 0.031) in the ZES group.
Although the proportion of dyslipidemia was higher in the
ZES group, the mean low-density cholesterol level was
similar between the 2 groups. In addition, the ZES group
Table 2. Baseline Angiographic Characteristics of Lesions in Diabetes Population*
Total
(N ¼ 2,688)
EES
(n ¼ 1,660)
ZES-R
(n ¼ 1,028) p Value
Target vessel location 0.127
Left main artery 97 (3.6) 69 (4.2) 28 (2.7)
LAD 1157 (43.0) 700 (42.2) 457 (44.5)
LCX 610 (22.7) 393 (23.7) 217 (21.1)
RCA 818 (30.4) 495 (29.8) 323 (31.4)
Bypass graft 6 (0.2) 3 (0.2) 3 (0.3)
ACC/AHA lesion class <0.001
A 204 (8.8) 87 (6.1) 117 (13.0)
B1 599 (25.7) 381 (26.7) 218 (24.2)
B2 616 (26.4) 381 (26.7) 235 (26.1)
C 910 (39.1) 579 (40.5) 331 (36.7)
Type B2 or C lesions* 1,526 (65.5) 960 (67.2) 566 (62.8) 0.032
In-stent restenosis 175 (6.5) 116 (7.0) 59 (5.8) 0.228
Severe calciﬁcation 267 (13.7) 174 (14.9) 93 (12.0) 0.080
Bifurcationy 352 (13.2) 169 (10.2) 183 (17.9) <0.001
Bifurcation treatment 140 (5.3) 70 (4.3) 70 (6.9) 0.004
Thrombus present 204 (8.4) 116 (7.9) 88 (9.1) 0.295
Small vesselz 558 (20.8) 350 (21.1) 208 (20.2) 0.625
Long lesionx 1,080 (40.2) 627 (37.8) 453 (44.1) 0.001
Maximum pressure deployment, atm 13.58  4.44 13.59  4.50 13.57  4.35 0.907
Mean stent diameter/lesion, mm 3.11  5.30 3.18  6.71 3.01  0.44 0.422
Total stent length, mm
Per patient 41.07  26.67 39.80  26.51 43.16  26.80 0.008
Per lesion 28.59  14.62 27.55  14.34 30.31  14.93 <0.001
Stents, n
Per patient 1.74  0.99 1.74  1.00 1.74  0.99 0.977
Per lesion 1.20  0.52 1.20  0.51 1.19  0.53 0.680
IVUS-guided stenting 988 (37.1) 621 (37.8) 367 (37.8) 0.364
Device success 2,623 (98.2) 1,619 (98.0) 1,004 (98.5) 0.370
Lesion success 2,624 (98.1) 1,618 (97.9) 1,006 (98.4) 0.383
Procedure success 2,621 (98.1) 1,615 (97.9) 1,006 (98.5) 0.244
Values are n (%) or mean  SD. *Type B2 or C lesions according to ACC/AHA classiﬁcation. yBifurcation means bifurcated lesion that has been treated
solely by drug-eluting stents. zSmall vessel denotes lesion with reference diameter 2.75 mm. xLong lesion denotes lesion with length 28 mm.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; IVUS ¼ intravascular ultrasound; LAD ¼ left anterior descending artery;
LCX ¼ left circumﬂex artery; RCA ¼ right coronary artery; other abbreviations as in Table 1.
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476had a slightly higher baseline risk, including higher fre-
quency of ST-segment elevation MI patients, bifurcation
lesions, and longer stent length. PCI was also more often
off-label in the ZES group. However, type B2 or C lesions
were more common in the EES group (Tables 1 and 2).
Overall, acute coronary syndrome accounted for 60.3%,
and PCI was off-label in 77.7% of the cases. Patients with
multivessel disease accounted for 62.8%, and the mean
stent length was 41.1  26.7 mm per patient, all of which
were signiﬁcantly higher in the patients with diabetes
than in nondiabetic patients in both stent groups. The
large proportion of high-risk patients and lesions suggests
that our study patients were an enriched PCI popula-
tion, reﬂecting real-world practice in Korea without any
exclusion or restriction. In addition, 37.1% of the cases
were performed under intravascular ultrasound guidance.Despite the large proportion of high-risk patients and le-
sions, the device, lesion, and procedure success rates were
excellent for both stents and did not show between-group
differences (Table 2).
Clinical outcomes at 1 year in crude population. In diabetic
patients, the TLF rate was 3.7% (43 of 1,149 patients) in the
EES group and 3.5% (25 of 706 patients) in the ZES group
(relative risk [RR]: 0.95, 95% conﬁdence interval [CI]:
0.58 to 1.54, p ¼ 0.899). The rates of the individual com-
ponents of TLF, cardiac death, TLR, and target vessel–
related MI were also similar between the 2 stent groups
(Table 3). The rate of patient-oriented composite events was
similar as well (9.1% vs. 10.2%, RR: 1.13, 95% CI: 0.85 to
1.50, p ¼ 0.416), as were the individual components (all-
cause death, any revascularization, any MI). Approximately
one-half of the cases of target vessel MI (5 of 11, 45.5%) were
Table 3. Clinical Outcomes in Diabetes Population at 1 Year
Total
(N ¼ 1,855)
EES
(n ¼ 1,149)
ZES-R
(n ¼ 706)
RR
(95% CI) p Value
Target lesion failure* 68 (3.7) 43 (3.7) 25 (3.5) 0.95 (0.58–1.54) 0.899
Patient-oriented composite eventsy 176 (9.5) 104 (9.1) 72 (10.2) 1.13 (0.85–1.50) 0.416
All-cause death 54 (2.9) 34 (3.0) 20 (2.8) 0.96 (0.56–1.65) 0.888
Cardiac death 32 (1.7) 21 (1.8) 11 (1.6) 0.85 (0.41–1.76) 0.717
Any MI 13 (0.7) 9 (0.8) 4 (0.6) 0.72 (0.22–2.34) 0.777
Target vessel 11 (0.6) 8 (0.7) 3 (0.4) 0.61 (0.16–2.29) 0.548
Nontarget vessel 2 (0.1) 1 (0.1) 1 (0.1) 1.63 (0.10–25.9) 0.728
MI due to ST 5 (0.3) 4 (0.3) 1 (0.1) 0.41 (0.05–3.63) 0.655
Any revascularization 124 (6.7) 71 (6.2) 53 (7.5) 1.21 (0.86–1.71) 0.292
Clinically driven revascularization 88 (4.7) 54 (4.7) 34 (4.8) 1.02 (0.67–1.56) 0.911
Target lesion revascularization 33 (1.8) 20 (1.7) 13 (1.8) 1.06 (0.53–2.11) 0.873
Target vessel revascularization 53 (2.9) 28 (2.4) 25 (3.5) 1.45 (0.85–2.47) 0.196
Cerebrovascular accident 16 (0.9) 11 (1.0) 5 (0.7) 0.74 (0.26–2.12) 0.619
Values are n (%). *Target lesion failure deﬁned as a composite of cardiac death, MI (not clearly attributed to a nontarget vessel), or clinically indicated target lesion revascularization by percutaneous or
surgical methods at 1 year. yPatient-oriented composite events included all-cause mortality, any MI (includes nontarget vessel territory), and any revascularization (includes all target and nontarget vessel,
regardless of percutaneous or surgical methods).
CI ¼ conﬁdence interval; MI ¼ myocardial infarction; RR ¼ relative risk; ST ¼ stent thrombosis.
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477due to ST (Table 3). In nondiabetic patients, the incidence
of TLF was also comparable between the 2 stent groups
(39 of 1,882 [2.1%] vs. 33 of 1,292 [2.6%], p ¼ 0.370), as
with patient-oriented composite events (119 of 1,882 [6.3%]
vs. 81 of 1,292 [6.3%], p ¼ 0.951). The rates of TLF and
patient-oriented composite events were both signiﬁcantly
higher in diabetics versus nondiabetics, regardless of stent
type (Fig. 2). However, both stent groups did not show
any differences in the cumulative incidence of TLF or
patient-oriented composite events, both in the diabetic and
nondiabetic patients (Fig. 2). The survival curves of indi-
vidual components of TLF or patient-oriented composite
events are presented in Online Figure 1.
The incidence of Academic Research Consortium–
deﬁned deﬁnite or probable ST through 1 year was very low,
regardless of diabetes: the rates of ST were 0.5% (10 of 1,855
patients) for the diabetic patients and 0.5% (15 of 3,174
patients) in the nondiabetic patients. In diabetic patients,
there was a numerically higher rate of deﬁnite or probable
ST in the EES group without statistical signiﬁcance (0.8%
vs. 0.1%, p ¼ 0.100) (Table 4). However, the incidence of
ST did not show any clustering of events in nondiabetic
patients (0.5% vs. 0.5%, p ¼ 0.956). All diabetic patients
with ST were on dual antiplatelet therapy, except in 1 case
in which both agents were discontinued due to spontaneous
subdural hemorrhage 2 days after PCI. A detailed description
of all ST cases in the patients with DM is presented in
Online Table 1.
Notably, the subgroup of insulin-treated patients (n ¼
255) showed similar rates of TLF and patient-oriented
composite events compared with the non-insulin-treated
patients (TLF: 4.3% vs. 3.6%, p ¼ 0.589, patient-oriented
composite events: 10.2% vs. 9.4%, p ¼ 0.730 for insulin- vs.non-insulin-treated patients, respectively). Conversely, pa-
tients with chronic renal failure showed signiﬁcantly higher
incidence of both TLF (9.3% vs. 3.3%, p < 0.01) and
patient-oriented composite events (14.7% vs. 9.2%, p ¼
0.038) (Fig. 3).
Propensity score matched group analysis. Propensity score
matching, according to the type of stents, yielded 934
patients (467 pairs) with more balanced baseline charac-
teristics (Online Table 2). All standardized differences
of the 44 adjusted variables were <10% (Online Fig. 2).
At 1 year, TLF occurred in 3.9% and 3.4% (RR: 0.89,
95% CI: 0.46 to 1.72, p ¼ 0.862) and patient-oriented
composite events in 9.4% and 8.6% (RR: 0.91, 95% CI:
0.60 to 1.37, p ¼ 0.732) in the EES and ZES groups,
respectively. The individual components of both TLF
and patient-oriented composite events, and the incidence
of deﬁnite and probable ST were also similar (Online
Table 3). In the survival analysis, cumulative incidences of
TLF or patient-oriented composite events were compa-
rable between the EES and ZES groups, regardless of the
presence of diabetes (Fig. 2).
To minimize the risk of bias in comparing diabetic and
nondiabetic patients, both groups were matched according
to the presence of DM. As a result, 2,774 patients were
matched (1,387 patients with or without DM, respectively)
with more balanced baseline characteristics (Online
Table 4). As expected, except for signiﬁcantly higher he-
moglobin A1C level in the diabetes group, standardized
differences of baseline characteristics were <10% (Online
Fig. 2). Both TLF (3.6% in diabetic patients vs. 1.9% in
nondiabetic patients, respectively, RR: 1.85, 95% CI: 1.17
to 2.94, p ¼ 0.008) and patient-oriented composite events
(9.0% vs. 6.2%, RR: 1.45, 95% CI: 1.12 to 1.89, p ¼ 0.005)
Figure 2. Kaplan-Meier Curves for Primary and Major Secondary Clinical Outcomes
(A) Target lesion failure in crude population. (B) Patient-oriented composite outcome in crude population. (C) Target lesion failure in propensity score matched
population. (D) Patient-oriented composite events in propensity score matched population. Event rates were presented as the cumulative incidence, which was
calculated from Kaplan-Meier estimates. DM ¼ diabetes mellitus; ZES ¼ zotarolimus-eluting stent(s); other abbreviations as in Figure 1.
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478were signiﬁcantly higher in the patients with diabetes
than in the nondiabetic patients (Online Table 5). In
addition, the patients with DM showed signiﬁcantly higher
incidence of target vessel MI and target vessel revasculari-
zation (Online Table 5).
Independent predictors of target lesion failure in the patients
with diabetes mellitus. In the multivariate Cox regression
model, chronic renal failure was the strongest predictor of
TLF (adjusted hazard ratio [HR]: 4.393, 95% CI: 1.913
to 10.09, p < 0.001). Other signiﬁcant predictors of TLF
included in-stent restenosis, left main coronary artery PCI,
and small vessel intervention, but not the type of stent itself
(HR: 0.92, 95% CI: 0.48 to 1.79, p ¼ 0.810) (Table 5,
Online Table 4). The overall Harrell C-index of the model
was 0.780 (95% CI: 0.699 to 0.861).Discussion
This is the ﬁrst comprehensive registry analysis evaluating
the safety and efﬁcacy of EES (Xience V EES) versus
ZES (Resolute ZES) in the patients with DM. Our results
demonstrated that EES and ZES showed comparable results
regarding stent- and patient-related composite outcomes at
1 year in the patients with DM, both in the crude and
propensity score matched populations. Although the in-
cidences of TLF or patient-oriented composite events were
signiﬁcantly higher in the patients with DM than in the
nondiabetic patients, the overall incidence was low, suggesting
excellent safety and efﬁcacy of both types of second-generation
DES in this high-risk subgroup of patients. In addition,
the patient-related outcomes were about 3-fold higher than
Table 4. Stent Thrombosis in Diabetes Population at 1 Year
Total
(N ¼ 1,855)
EES
(n ¼ 1,149)
ZES-R
(n ¼ 706)
p
Value
Deﬁnite 4 (0.2) 4 (0.3) 0 (0.0) 0.304
Acute, 0–1 day 2 (0.1) 2 (0.2) 0 (0.0) 0.528
Subacute, 2–30 days 1 (0.1) 1 (0.1) 0 (0.0) >0.999
Late, 31–360 days 1 (0.1) 1 (0.1) 0 (0.0) >0.999
Probable 6 (0.3) 5 (0.4) 1 (0.1) 0.417
Acute, 0–1 day 0 (0.0) 0 (0.0) 0 (0.0) NA
Subacute, 2–30 days 6 (0.3) 5 (0.4) 1 (0.1) 0.417
Late, 31–360 days 0 (0.0) 0 (0.0) 0 (0.0) NA
Stent thrombosis*
Deﬁnite or Probable 10 (0.5) 9 (0.8) 1 (0.1) 0.100
Duration of dual
antiplatelet agent
For 6 months 1,534 (95.9) 956 (95.9) 578 (95.9) >0.999
For 1 year 1,342 (83.9) 836 (83.9) 506 (83.9) >0.999
Mean duration
of DAPT
348.13  68.84 348.27  69.82 347.89  67.24 0.914
Values are n (%) or mean  SD. *Detailed description of stent thrombosis is presented
in Online Table 1.
DAPT ¼ dual antiplatelet agent therapy; NA ¼ not applicable; other abbreviations as
in Table 1.
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479the stent-related outcomes (TLF) were, suggesting the im-
portance of secondary prevention and integrated medical
management of comorbidities along with DM, including
diabetic nephropathy, hypertension, and peripheral arterial
disease. Finally, the chronic renal failure was the strongest
predictor of TLF within 1 year in the patients with DM.Figure 3. Exploratory Subgroup Analysis for Target Lesion Failure
AMI ¼ acute myocardial infarction; CI ¼ conﬁdence interval; HR ¼ hazard ratio; PCI
myocardial infarction; other abbreviations as in Figures 1 and 2.The safety and efﬁcacy of the second-generation DES in
the patients with DM have been continuously evaluated.
The EES was shown to be noninferior to sirolimus-eluting
stent for in-segment late loss at 8 months in the
ESSENCE-DIABETES (Randomized Comparison of
Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent
Implantation for De Novo Coronary Artery Disease in Pa-
tients With Diabetes Mellitus) trial (7). Although under-
powered for clinical outcomes, death, MI, and TLR were
not signiﬁcantly different between EES (Xience V) and
sirolimus-eluting stents. Also post-hoc subgroup analysis
from 4 pooled RCT, comparing EES versus paclitaxel-
eluting stent, showed no difference in clinical outcomes after
2 years of follow-up between EES and paclitaxel-eluting
stents (8). On the other hand, ZES (Resolute) have showed
signiﬁcantly lower incidence of target vessel failure at 1 year
(7.8%) than the pre-deﬁned DES performance goal of
14.5% in the patients with DM and achieved the ﬁrst U.S.
Food and Drug Administration approval for PCI in patients
with diabetes (9). Although both of the second-generation
DES, compared with ﬁrst generation DES, have shown
improved clinical outcomes in the diabetic patients, the data
regarding head-to-head comparison of these stents in the
patients with DM have been limited. The representative
direct comparisons of EES versus ZES (i.e., Resolute All-
Comers and TWENTE trials) did not focus on the diabetic
subgroup. The proportion of the patients with DM was
limited to 538 patients (23.4%) in the Resolute All-Comers
trial and 301 patients (21.6%) in the TWENTE trial, which¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation
Table 5. Independent Predictors of Target Lesion Failure in
Diabetes Population*
Hazard Ratio 95% CI p Value
Chronic renal failure 4.393 1.913–10.09 <0.001
In-stent restenosis 4.226 1.843–9.690 0.001
Left main vessel PCI 4.082 1.561–10.68 0.004
Vessel diameter 2.75 mm 2.690 1.325–5.463 0.006
EES versus ZES-Ry 0.922 0.475–1.788 0.810
*Included variables are presented in Online Table 6. yHazard ratio of EES over ZES-R in crude
population. In propensity score matched group, the hazard ratio of EES over ZES-R was 1.237
(95% CI: 0.595 to 2.571, p ¼ 0.570).
Abbreviations as in Tables 1 and 3.
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480were relatively underpowered to compare clinical outcomes
in the diabetic population. In addition, it is well known
that patients with higher-risk proﬁles and higher early in-
hospital mortality tend to be excluded from participation in
clinical trials, even with all-comers design (19). We evalu-
ated 1,855 diabetics with 2,688 lesions, and the majority of
patients had 1 off-label indication (77.7%), and there was
no restriction or exclusion criteria regarding disease severity
or lesion complexity. In addition, over 98% of the patients
were strictly followed, and the survival status of all patients
was thoroughly investigated. In this regard, this analysis
of prospective observational registries has the strength of
including a broader patient population with quite a large
sample size, which is more reﬂective of everyday practice,
compared with former RCT.
Interestingly, insulin-treated patients showed numerically
higher but statistically insigniﬁcant rates of TLF and
patient-oriented composite events. Previous trials using
sirolimus-eluting stents (SIRIUS [Sirolimus-Coated Bx
Velocity Balloon-Expandable Stent in the Treatment of
Patients With De Novo Coronary Artery Lesions] and
DIABETES [Diabetes and Sirolimus-Eluting Stent]) have
shown conﬂicting results regarding whether insulin-treated
patients show increased risk of adverse outcome (1,2). Also,
pooled analysis of EES versus PES from the SPIRIT
(Clinical Evaluation of the Xience V Everolimus Eluting
Coronary Stent System in the Treatment of Patients With
De Novo Native Coronary Artery Lesions) II, III, IV and
the COMPARE (Cozaar in Marfan Patients Reduces
Aortic Enlargement) trials showed no signiﬁcant difference
in 2-year hard clinical endpoints (cardiac death, MI, or ST)
according to insulin treatment; however, signiﬁcant inter-
action existed between diabetes treatment and stent type (8).
Conversely, recent pooled analysis of patient-level data
from the RESOLUTE Global Clinical Program showed
signiﬁcantly higher incidence of target vessel failure (16.4%
versus 10.4%, p ¼ 0.02) or TLF (13.5% versus 7.9%,
p ¼ 0.01), mainly driven by higher incidence of cardiac
death or target vessel MI (3.9% vs. 8.6%, p ¼ 0.01), in the
insulin-treated patients after 2 years following ZESimplantation (9). Whether insulin-dependency signiﬁcantly
affects outcome of PCI with second-generation DES needs
to be clariﬁed in larger-scale data.
On multivariate analysis, several factors were found to
signiﬁcantly increase the risk of TLF including chronic renal
failure, in-stent restenosis, left main vessel PCI, and small
vessel diameter. Chronic renal failure and left main vessel
PCI have been well-recognized risk factors for major adverse
cardiac events (20) and angiographic restenosis (21) after
stent implantation in both the bare-metal stent era and
the ﬁrst-generation DES era. Small vessel stenting may
lead to increased risk of periprocedural myocardial necrosis
and has been reported to be a risk factor for ST (22).
Because diabetic patients tend to have smaller vessel di-
ameters, this could adversely affect the long-term clinical
outcomes, as was corroborated in our results. Treatment of
in-stent restenosis requires stent implantation in an area that
has previously been stented. This can result in injury zone
mismatch, a gap between the stents, fracture of the stent,
polymer disruption, or a combination of these mechanisms
(23). Thus, treatment of in-stent restenosis lesions still
remains a challenge even in the DES era. All things
considered, however, the low rates of both stent- and
patient-oriented outcomes in the present analysis reafﬁrms
that the development of a new generation of DES has been
in the right direction. Nonetheless, more investigation about
long-term clinical outcomes after PCI with second-genera-
tion DES in insulin-treated diabetic patients is needed.
Study limitations. First, this was a nonrandomized com-
parison of 2 different registries. Therefore, this study cannot
be free from inherent limitations of observational registries
such as allocation bias and uneven distribution of risk fac-
tors. Although we used propensity score matching to
minimize the allocation bias and control for potential con-
founding variables, the possibilities of uncontrolled and
unknown confounding factors need to be considered. Sec-
ond, analysis of clinical outcome was limited to 1 year after
index PCI. Our study is not able to make any conclusions
regarding long-term prognosis over 1 year in diabetic pa-
tients. Further follow-up is required, especially to address
safety issues such as ST. Third, because data were from
observational registries, the clinical events may not have been
captured with scrutiny, and patient follow-up may not have
been as strict as would be in a randomized trial. This may
have been the reason for the low event rates, especially the
rate of target lesion–related MI, which was much lower in
our study than in the previous RCT and pooled analysis
of EES and ZES (8–11). We believe that this may be due
to the fact that systematic collection of cardiac enzymes after
PCI is not the routine practice in Korea. Some centers even
discharge their patients on the same day after PCI via the
radial approach. Therefore, we believe the true rate of MI
would have been much higher if the cardiac enzymes were
followed systematically. Although we cross-checked the vital
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 5 , 2 0 1 4 Park et al.
M A Y 2 0 1 4 : 4 7 1 – 8 1 EES Versus ZES in Patients With Diabetes Mellitus
481status of 100% of the study patients with the Korean na-
tional database using a citizen registration number that
is unique to each individual, we cannot exclude the possi-
bility of under-reporting of clinical outcomes other than
death such as MI, TLR, or most importantly, ST, in the
patients who were lost to follow-up but are still alive. Lastly,
although we thoroughly collected baseline and discharge
medication data including dual antiplatelet agents, we did
not include cilostazol as 1 of the parameters to collect,
therefore, the clinical efﬁcacy of triple antiplatelet agent
in diabetic patients could not be evaluated.Conclusions
After unrestricted use of second-generation DES in all-
comers receiving PCI, both EES and ZES showed com-
parable clinical outcomes in the patients with DM up to
1 year of follow-up. The patients with DM showed signif-
icantly worse patient- and stent-related outcomes than did
the nondiabetic patients. Nonetheless, overall incidences
of target lesion failure were low, even in the patients with
DM, suggesting excellent safety and efﬁcacy of both types
of second-generation DES in this high-risk subgroup of
patients.
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APPENDIX
For supplemental study methods, ﬁgures, and tables, please see the online
version of this paper.
